ClinicalTrials.gg
CompletedNCT01423916Updated Oct 29, 2015Results posted

Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder

A Phase 1 interventional study of OPC-34712 (4mg) and Moxifloxacin in Schizophrenia and Schizoaffective Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2015-10-29.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.

Enrollment
13th of 28
218 · median 155
Started
2011
with 6 others
Phase 1
8 of 28
1 open now
Registered
8th of 28
by date
Lead sponsor
19 of 28
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 13th largest by enrollment, is one of 7 that started in 2011, is one of 8 in phase 1, and was the 8th registered.

Schizophrenia

3,567 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing brexpiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to establish pharmacodynamics (PD), pharmacokinetics (PK), and adverse event (AE) profile of OPC-34712 administered to schizophrenic/schizoaffective subjects. The goals of this trial are three-fold:

  • To determine the effect of OPC-34712 on the individual QT interval (QTcI) corrected for placebo
  • To determine the effect of moxifloxacin on QTcI
  • To examine the concentration-effect relationship of OPC-34712 and moxifloxacin on QTcI
03

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorder

Keywords

  • Schizophrenia
  • QTc Interval
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects between 18 and 55 years of age, inclusive, with a diagnosis of schizophrenia or schizoaffective disorder as defined by criteria.
  • of 19 to 35 kg/m2.

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant or lactating. A negative serum pregnancy test must be confirmed prior to the first dose of trial medication for all female subjects.
  • Subjects presenting with a first episode of schizophrenia or schizoaffective disorder based on the clinical judgment of the investigator.
  • Subjects who have received continuous medication therapy to treat schizophrenia or schizoaffective disorder for less than 6 months prior to washout.
  • Subjects with schizophrenia or schizoaffective disorder that are considered resistant/ to antipsychotic treatment by history, who have a history of failure to clozapine, or who are responsive only to clozapine treatment.
  • Subjects with a current Axis I diagnosis other than schizophrenia or schizoaffective disorder.
  • Hospitalization for an exacerbation of schizophrenia or schizoaffective disorder within 3 months prior to randomization.
  • Subjects who have a history of or who have evidence of other medical and/or neurological conditions that would expose them to an undue risk of a significant AE or interfere with assessments of safety or efficacy during the course of the trial.
  • Subjects with a history of neuroleptic malignant syndrome.
  • Subjects with a history of seizure disorder.
  • Subjects who meet DSM-IV-TR criteria for substance dependence within 6 months prior to randomization.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
218 participants (actual)

Study arms

  • Active comparator
    Arm 1 (OPC-34712, placebo)

    Arm 1 will be administered 4 mg OPC-34712 once daily (QD) for 11 days and OPC-34712 placebo for 1 day.

    Drug: OPC-34712 (4mg) · Drug: Placebo

  • Active comparator
    Arm 2 (OPC-34712, placebo)

    Arm 2 will be administered 12 mg OPC-34712 QD for 11 days and OPC-34712 placebo for 1 day.

    Drug: OPC-34712 (12mg) · Drug: Placebo

  • Active comparator
    Arm 3 (moxifloxacin, placebo)

    Arm 3 will be administered 400 mg moxifloxacin (positive control) plus OPC-34712 placebo for 1 day and OPC-34712 placebo QD for 11 days.

    Drug: Moxifloxacin · Drug: Placebo

  • Active comparator
    Arm 4 (moxifloxacin, placebo)

    Arm 4 will be administered OPC-34712 placebo QD for 11 days and 400 mg moxifloxacin (positive control) plus OPC-34712 placebo for one day.

    Drug: Moxifloxacin · Drug: Placebo

Interventions

  • Arms assigned to this intervention receive 4mg.

  • Arms assigned to this intervention will receive 400mg.

  • Arms assigned to this intervention receive 12mg.

  • DrugPlacebo

    OPC-34712 placebo

06

What researchers measure

Primary outcomes

  1. Time-matched QTcI Change From Baseline (Day -1) Corrected for Placebo on Day 11 Following Brexpiprazole Treatment.

    Pharmacodynamics endpoint is the time-matched corrected QT interval (QTcI) change from baseline (Day -1) corrected for placebo on Day 11 following brexpiprazole treatment. The primary QT to QTc correction formula (QTcI) was determined for each participant using the participant's baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k was derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k).

    Time frame: Day 11 (Hours 1, 2, 3, 4, 5, 6, 8, 12, 16, 24)

  2. Number of Participants With Adverse Events (AE) and Clinically Important Changes in Vital Signs, Physical Examinations, Laboratory Tests, and Standard ECGs (Electrocardiogram).

    Clinically important changes in vital signs, physical examinations, laboratory tests and ECGs were by and large reflected in AE/SAE (which are presented in safety section) of this report.

    Time frame: AEs were recorded from Screening (informed consent was signed) during the 12-day treatment period to follow-up 30 (+ 2) days post-last dose of study medication

  3. Maximum Peak Plasma Concentration (Cmax) of Brexpiprazole and Moxifloxacin.

    Pharmacokinetics endpoint is the maximum (peak) plasma concentration (Cmax) of brexpiprazole and moxifloxacin. Values for Cmax were determined directly from the observed data. Blood samples were collected on Days -1, 1, 11, and 12 at predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose or at ET.

    Time frame: Day 11

  4. Time to Maximum (Peak) Plasma Concentration (Tmax) of Brexpiprazole and Moxifloxacin.

    Pharmacokinetics endpoint is the time to maximum (peak) plasma concentration (tmax) of brexpiprazole and moxifloxacin. Values for tmax were determined directly from the observed data. Blood samples were collected on Days -1, 1, 11, and 12 at predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose or at ET.

    Time frame: Day 11

  5. Area Under the Plasma Concentration-time Curve During Dosing (AUCT).

    Pharmacokinetics endpoint is the area under the concentration-time curve from time zero to 24 hours (AUC0-24h) of brexpiprazole and moxifloxacin. Area under the plasma concentration-time curve during the dosing interval at steady-state (AUCT) value was estimated using the linear trapezoidal rule; the value reported represent the area under the curves to the last time point during that day. Blood samples were collected on Days -1, 1, 11, and 12 at predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose or at ET.

    Time frame: Day 11

Secondary outcomes

  1. Number of Participants Noted With Time-matched Change in Mean QTcI Change From Baseline for Assay Sensitivity of Moxifloxacin Treatment Corrected for Placebo at Day 11.

    New onset (\> 450, \> 480, or \> 500 msec) in QTc was defined as a participant who attained a QTc \> 450, \> 480, \> 500 msec during Day 11 but not on Day -1. The number of participants were noted with time-matched change in mean QTcI change from Baseline for assay sensitivity of moxifloxacin treatment corrected for placebo. The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k).

    Time frame: Baseline, Day 11

  2. Change From Baseline in Summary of Maximum QTcI on Day 11 Minus Mean QTcI on Day -1 (Baseline).

    The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k). The change form Baseline in summary of maximun QTcI on Day 11 minus mean QTcI on Day -1 (Baseline) is presented here.

    Time frame: Baseline, Day 11

  3. Change From Baseline in Summary of Maximum QTcI on Day 11 Minus Maximum QTcI on Day -1 (Baseline).

    The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k). The change from Baseline in summary of maximum QTcI on Day 11 minus maximum QTcI on Day -1 (Baseline) is presented here.

    Time frame: Baseline, Day 11

  4. Number of Participants With QTcI Interval Between 30 and 60 Msec on Day 11.

    The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k). Participants with QTcI interval change between 30 to 60 msec were presented here.

    Time frame: Day 11

  5. Number of Participants With QTcI Interval > 60 Msec on Day 11.

    The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k). Participants with QTcI interval change of \> 60 msec on Day 11 were presented here.

    Time frame: Day 11

  6. Number Participants Noted With New Incidence of QT Interval of > 500 Msec on Day 11.

    The number of participants who were noted with new incidence of QT interval of \> 500 msec on Day 11 and a 12-lead ECG was used.

    Time frame: Day 11

  7. Number of Participants With New Incidence of ECG Morphology Abnormalities on Day 11.

    Participants with incidence of ECG morphology abnormalities on Day 11 (participants who had abnormalities during Day 11 but not at Day -1) were noted. Types of abnormalities included appearance of abnormal U waves, negative T waves, elevation of ST segment, depression of ST segment, second degree heart block, third degree heart block, right bundle branch block, and left bundle branch block. ECGs were sampled at predose and approximately 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose on Days -1, 1, 11, and 12.

    Time frame: Day 11

  8. Number of Participants With Maximum Change From Baseline to the On-treatment ECG Values on Day 11 for Heart Rate (HR), PR Interval, and QRS Interval.

    Changes in HR with values 25% decrease from Day -1 and HR \< 50 bpm and 25% increase from Day -1 and HR \> 100 bpm; PR interval of greater than or equal to 25% change from Day -1 and PR \> 200 msec; QRS interval of Greater than or equal to 25% change from Day -1 and \> 100 msec were noted on Day 11. Maximum change from baseline to the on-treatment ECG values on Day 11 for heart rate.

    Time frame: Day 11

07

Results

Posted Oct 29, 2015

Participant flow

A randomized, double-blind, placebo and positive-controlled, parallel-arm study to examine the effects of 2 dose levels of brexpiprazole on the QT/QTc (QT interval corrected for heart rate) interval. This study was run in 8 sites in the US.

Participant flow — Overall Study
MilestoneBrexpiprazole 4mgBrexpiprazole 12mgMoxifloxacin/Placebo
Started747371
Completed635364
Not completed11207
Withdrew: Adverse event592
Withdrew: Met withdrawal criteria111
Withdrew: Physician decision101
Withdrew: Withdrawal by subject3103
Withdrew: Protocol deviation100

Outcome measures

PrimaryTime-matched QTcI Change From Baseline (Day -1) Corrected for Placebo on Day 11 Following Brexpiprazole Treatment.

Pharmacodynamics endpoint is the time-matched corrected QT interval (QTcI) change from baseline (Day -1) corrected for placebo on Day 11 following brexpiprazole treatment. The primary QT to QTc correction formula (QTcI) was determined for each participant using the participant's baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k was derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k).

Time frame:
Day 11 (Hours 1, 2, 3, 4, 5, 6, 8, 12, 16, 24)
Reported as:
Mean · msec
Time-matched QTcI Change From Baseline (Day -1) Corrected for Placebo on Day 11 Following Brexpiprazole Treatment.
msecMoxifloxacin/PlaceboBrexpiprazole 12mgBrexpiprazole 4mg
Hours 1 (N=61, 53, 61)9.2 (5.8 to 12.6)-0.2 (-5.2 to 4.8)2.6 (-2.2 to 7.4)
Hours 2 (N= 62, 53, 62)9.4 (6.0 to 12.8)-0.2 (-5.0 to 4.5)1.2 (-3.4 to 5.7)
Hours 3 (N= 60, 51, 61)8.5 (5.1 to 11.9)1.3 (-3.4 to 6.0)1.1 (-3.4 to 5.6)
Hours 4 (N= 62, 53, 62)10.5 (7.1 to 13.8)3.1 (-1.7 to 8.0)3.6 (-1.0 to 8.3)
Hours 5 (N= 62, 52, 62)6.2 (2.8 to 9.5)-0.2 (-5.1 to 4.6)1.7 (-2.9 to 6.3)
Hours 6 (N= 61, 52, 62)7.3 (3.8 to 10.7)1.3 (-3.5 to 6.1)8.3 (-3.7 to 12.9)
Hours 8 (N= 59, 50, 59)7.5 (4.1 to 10.9)2.5 (-2.0 to 6.9)4.0 (-0.2 to 8.3)
Hours 10 (N= 59, 47, 56)9.0 (5.5 to 12.4)2.2 (-2.3 to 6.8)5.2 (0.8 to 9.5)
Hours 12 (N= 58, 47, 58)6.8 (3.3 to 10.3)2.6 (-2.2 to 7.4)5.3 (0.7 to 9.9)
Hours 16 (N= 59, 48, 53)2.2 (-1.3 to 5.7)0.8 (-3.9 to 5.5)4.0 (-0.6 to 8.5)
Hours 24 (N= 54, 45, 57)2.1 (-1.5 to 5.7)0.7 (-4.2 to 5.7)0.1 (-4.6 to 4.8)
PrimaryNumber of Participants With Adverse Events (AE) and Clinically Important Changes in Vital Signs, Physical Examinations, Laboratory Tests, and Standard ECGs (Electrocardiogram).

Clinically important changes in vital signs, physical examinations, laboratory tests and ECGs were by and large reflected in AE/SAE (which are presented in safety section) of this report.

Time frame:
AEs were recorded from Screening (informed consent was signed) during the 12-day treatment period to follow-up 30 (+ 2) days post-last dose of study medication
Reported as:
Number · participants
Number of Participants With Adverse Events (AE) and Clinically Important Changes in Vital Signs, Physical Examinations, Laboratory Tests, and Standard ECGs (Electrocardiogram).
participantsBrexpiprazole 4mgBrexpiprazole 12mgMoxifloxacinPlacebo
Postural orthostatic tachycardia syndrome0100
Tachycardia0021
Blood creatinine phosphokinase increased1100
Blood pressure increased0001
Blood prolactin increased0010
Hepatic enzyme increased1100
Liver function test abnormal0100
Weight increased0100
Hyperglycaemia0100
PrimaryMaximum Peak Plasma Concentration (Cmax) of Brexpiprazole and Moxifloxacin.

Pharmacokinetics endpoint is the maximum (peak) plasma concentration (Cmax) of brexpiprazole and moxifloxacin. Values for Cmax were determined directly from the observed data. Blood samples were collected on Days -1, 1, 11, and 12 at predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose or at ET.

Time frame:
Day 11
Reported as:
Mean · ng/mL
Maximum Peak Plasma Concentration (Cmax) of Brexpiprazole and Moxifloxacin.
ng/mLBrexpiprazole 4mgBrexpiprazole 12mgMoxifloxacin/ Placebo
Maximum Peak Plasma Concentration (Cmax) of Brexpiprazole and Moxifloxacin.170 ± 69.8462 ± 2492760 ± 659
PrimaryTime to Maximum (Peak) Plasma Concentration (Tmax) of Brexpiprazole and Moxifloxacin.

Pharmacokinetics endpoint is the time to maximum (peak) plasma concentration (tmax) of brexpiprazole and moxifloxacin. Values for tmax were determined directly from the observed data. Blood samples were collected on Days -1, 1, 11, and 12 at predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose or at ET.

Time frame:
Day 11
Reported as:
Median · Hours
Time to Maximum (Peak) Plasma Concentration (Tmax) of Brexpiprazole and Moxifloxacin.
HoursBrexpiprazole 4mgBrexpiprazole 12mgMoxifloxacin/ Placebo
Time to Maximum (Peak) Plasma Concentration (Tmax) of Brexpiprazole and Moxifloxacin.3.54 (1.00 to 8.00)3.00 (0.00 to 8.00)1.25 (0.00 to 5.00)
PrimaryArea Under the Plasma Concentration-time Curve During Dosing (AUCT).

Pharmacokinetics endpoint is the area under the concentration-time curve from time zero to 24 hours (AUC0-24h) of brexpiprazole and moxifloxacin. Area under the plasma concentration-time curve during the dosing interval at steady-state (AUCT) value was estimated using the linear trapezoidal rule; the value reported represent the area under the curves to the last time point during that day. Blood samples were collected on Days -1, 1, 11, and 12 at predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose or at ET.

Time frame:
Day 11
Reported as:
Mean · ng*h/mL
Area Under the Plasma Concentration-time Curve During Dosing (AUCT).
ng*h/mLBrexpiprazole 4mgBrexpiprazole 12mgMoxifloxacin/ Placebo
Area Under the Plasma Concentration-time Curve During Dosing (AUCT).3100 ± 14008880 ± 511028400 ± 6350
SecondaryNumber of Participants Noted With Time-matched Change in Mean QTcI Change From Baseline for Assay Sensitivity of Moxifloxacin Treatment Corrected for Placebo at Day 11.

New onset (\> 450, \> 480, or \> 500 msec) in QTc was defined as a participant who attained a QTc \> 450, \> 480, \> 500 msec during Day 11 but not on Day -1. The number of participants were noted with time-matched change in mean QTcI change from Baseline for assay sensitivity of moxifloxacin treatment corrected for placebo. The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k).

Time frame:
Baseline, Day 11
Reported as:
Number · participants
Number of Participants Noted With Time-matched Change in Mean QTcI Change From Baseline for Assay Sensitivity of Moxifloxacin Treatment Corrected for Placebo at Day 11.
participantsBrexpiprazole 4mgBrexpiprazole 12mgMoxifloxacin 400 mgPlacebo
QTcI (> 450 msec)5450
QTcI (> 480 msec)0100
QTcI (> 500 msec)0000
SecondaryChange From Baseline in Summary of Maximum QTcI on Day 11 Minus Mean QTcI on Day -1 (Baseline).

The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k). The change form Baseline in summary of maximun QTcI on Day 11 minus mean QTcI on Day -1 (Baseline) is presented here.

Time frame:
Baseline, Day 11
Reported as:
Mean · msec
Change From Baseline in Summary of Maximum QTcI on Day 11 Minus Mean QTcI on Day -1 (Baseline).
msecBrexpiprazole 4mgBrexpiprazole 12mgMoxifloxacin 400mgPlacebo
Change From Baseline in Summary of Maximum QTcI on Day 11 Minus Mean QTcI on Day -1 (Baseline).11.6 ± 7.412.4 ± 10.410.6 ± 7.7-1.1 ± 13.1
SecondaryChange From Baseline in Summary of Maximum QTcI on Day 11 Minus Maximum QTcI on Day -1 (Baseline).

The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k). The change from Baseline in summary of maximum QTcI on Day 11 minus maximum QTcI on Day -1 (Baseline) is presented here.

Time frame:
Baseline, Day 11
Reported as:
Mean · msec
Change From Baseline in Summary of Maximum QTcI on Day 11 Minus Maximum QTcI on Day -1 (Baseline).
msecBrexpiprazole 4mgBrexpiprazole 12mgMoxifloaxcin 400mgPlacebo
Change From Baseline in Summary of Maximum QTcI on Day 11 Minus Maximum QTcI on Day -1 (Baseline).0.4 ± 9.10.9 ± 10.90.0 ± 8.1-1.2 ± 8.0
SecondaryNumber of Participants With QTcI Interval Between 30 and 60 Msec on Day 11.

The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k). Participants with QTcI interval change between 30 to 60 msec were presented here.

Time frame:
Day 11
Reported as:
Number · participants
Number of Participants With QTcI Interval Between 30 and 60 Msec on Day 11.
participantsBrexpiprazole 4mgBrexpiprazole 12mgMoxifloxacin 400mgPlacebo
Number of Participants With QTcI Interval Between 30 and 60 Msec on Day 11.41112
SecondaryNumber of Participants With QTcI Interval > 60 Msec on Day 11.

The primary QT to QTc correction formula (QTcI) were determined for each participant using the participant's Baseline (Day -1 placebo) ECG data. The QT correction formula QT / (RR)k were derived using log-log-linear regression, where log (QT) = a + k × log (RR) + ε to estimate the exponent (k). Participants with QTcI interval change of \> 60 msec on Day 11 were presented here.

Time frame:
Day 11
Reported as:
Number · participants
Number of Participants With QTcI Interval > 60 Msec on Day 11.
participantsBrexpiprazole 4mgBrexpiprazole 12mgMoxifloxacin 400mgPlacebo
Number of Participants With QTcI Interval > 60 Msec on Day 11.0000
SecondaryNumber Participants Noted With New Incidence of QT Interval of > 500 Msec on Day 11.

The number of participants who were noted with new incidence of QT interval of \> 500 msec on Day 11 and a 12-lead ECG was used.

Time frame:
Day 11
Reported as:
Number · participants
Number Participants Noted With New Incidence of QT Interval of > 500 Msec on Day 11.
participantsBrexpiprazole 4mgBrexpiprazole 12mgMoxifloxacin 400mgPlacebo
Number Participants Noted With New Incidence of QT Interval of > 500 Msec on Day 11.0000
SecondaryNumber of Participants With New Incidence of ECG Morphology Abnormalities on Day 11.

Participants with incidence of ECG morphology abnormalities on Day 11 (participants who had abnormalities during Day 11 but not at Day -1) were noted. Types of abnormalities included appearance of abnormal U waves, negative T waves, elevation of ST segment, depression of ST segment, second degree heart block, third degree heart block, right bundle branch block, and left bundle branch block. ECGs were sampled at predose and approximately 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose on Days -1, 1, 11, and 12.

Time frame:
Day 11
Reported as:
Number · participants
Number of Participants With New Incidence of ECG Morphology Abnormalities on Day 11.
participantsBrexpiprazole 4mgBrexpiprazole 12mgMoxifloxacin 400mgPlacebo
U Wave abnormalities0000
Negative T Waves4786
Depression of ST segment2241
Elevation of ST segment0000
Second degree heart block0000
Third degree heart block0000
Right bundle branch block0000
Left bundle branch block0000
SecondaryNumber of Participants With Maximum Change From Baseline to the On-treatment ECG Values on Day 11 for Heart Rate (HR), PR Interval, and QRS Interval.

Changes in HR with values 25% decrease from Day -1 and HR \< 50 bpm and 25% increase from Day -1 and HR \> 100 bpm; PR interval of greater than or equal to 25% change from Day -1 and PR \> 200 msec; QRS interval of Greater than or equal to 25% change from Day -1 and \> 100 msec were noted on Day 11. Maximum change from baseline to the on-treatment ECG values on Day 11 for heart rate.

Time frame:
Day 11
Reported as:
Number · participants
Number of Participants With Maximum Change From Baseline to the On-treatment ECG Values on Day 11 for Heart Rate (HR), PR Interval, and QRS Interval.
participantsBrexpiprazole 4mgBrexpiprazole 12mgMoxifloxacinPlacebo
HR: < 50 bpm0000
HR: > 100 bpm5724
PR > 200 msec0000
QRS > 100 msec0000

Adverse events

Collected over AEs were recorded from Screening (informed consent was signed) throughout the 12-day treatment period until follow-up of up to 30 (+ 2) days post-last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole 4mg—1/70 (1.4%)27/70 (38.6%)
Brexpiprazole 12mg—0/67 (0%)27/67 (40.3%)
Moxifloxacin—0/65 (0%)9/65 (13.8%)
Placebo—0/68 (0%)20/68 (29.4%)
Most frequent serious events
Most frequent serious events
EventBrexpiprazole 4mgBrexpiprazole 12mgMoxifloxacinPlacebo
Schizoaffective disorderPsychiatric disorders1/700/670/650/68
Most frequent other events
Most frequent other events
EventBrexpiprazole 4mgBrexpiprazole 12mgMoxifloxacinPlacebo
DizzinessNervous system disorders6/708/672/651/68
NauseaGastrointestinal disorders7/705/671/654/68
Application site dermatitisGeneral disorders6/701/672/654/68
AkathisiaNervous system disorders5/705/671/651/68
Extrapyramidal disorderNervous system disorders4/705/670/651/68
RestlessnessPsychiatric disorders2/705/670/653/68
HeadacheNervous system disorders1/705/672/654/68
ConstipationGastrointestinal disorders3/704/671/651/68
SomnolenceNervous system disorders3/704/671/651/68
InsomniaPsychiatric disorders3/704/670/653/68

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Brexpiprazole 4mgBrexpiprzole 12mgMoxifloxacin/PlaceboTotal
Mean38.5 ± 9.637.5 ± 9.038.2 ± 9.638.1 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole 4mgBrexpiprzole 12mgMoxifloxacin/PlaceboTotal
Female18161549
Male565756169
08

Study locations

8 sites
  • Otsuka Investigational Site
    Long Beach, California 90806, United States
  • Otsuka Investigational Site
    San Diego, California 92102, United States
  • Otsuka Investigational Site
    Fort Lauderdale, Florida 33308, United States
  • Otsuka Investigational Site
    Overland Park, Kansas 66212, United States
  • Otsuka Investigational Site
    Rockville, Maryland 20850, United States
  • Otsuka Investigational Site
    St. Louis, Missouri 63118, United States
  • Otsuka Investigational Site
    Philadelphia, Pennsylvania 19139, United States
  • Otsuka Investigational Site
    Austin, Texas 78754, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Feb 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2011
First posted
Aug 26, 2011
Start
Jul 2011
Primary completionActual
Feb 2012
CompletionActual
Mar 2012
Results first posted
Oct 29, 2015
Last update
Oct 29, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01423916
Responsible party
Sponsor
First posted
Aug 26, 2011
Start date
Jul 2011
Primary completion
Feb 2012
Completion
Mar 2012
Results posted
Oct 29, 2015
Last update
Oct 29, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brexpiprazole · Moxifloxacin

Start the discussion